Psychedelic drugs may exert their effects at intracellular serotonin receptors that serotonin itself, which does not cross cell membranes, cannot reach. The findings were published in the Feb. 17, 2023, issue of Science by researchers from the University of California at Davis.
The steadily percolating psychedelic drug space stands poised to generate a near-term stream of potentially encouraging developments in a range of mental health disorders, including depression, anxiety, post-traumatic stress disorder and more.
Psychedelic drugs may exert their effects at intracellular serotonin receptors that serotonin itself, which does not cross cell membranes, cannot reach. The findings were published in the Feb. 17, 2023, issue of Science by researchers from the University of California at Davis. An accompanying editorial by Evan Hess and Todd Gould at the University of Maryland School of Medicine called them “a key achievement in the understanding of the mechanism of action of psychedelics” and “an important step forward for a rapidly expanding and much-needed field of study.”
Medicinal cannabis company Zelira Therapeutics Ltd. secured $8.6 million in cornerstone funding from U.S.-based Cantheon Capital LLC that will progress Zelira’s Hope1 cannabinoid medicine to formal phase II/III clinical trials for behaviors associated with autism spectrum disorder.
Fresh off an end-of-year IPO, Coya Therapeutics Inc. is gearing up for clinical testing with its lead Treg-enhancing biologic in neurodegenerative disease, aiming to build on a wealth of academic-generated data highlighting the potential of Treg therapy to attack the neuroinflammation underlying diseases such as amyotrophic lateral sclerosis and Alzheimer’s disease.
Ryne Biotechnology Inc. has been awarded a US$4 million Clinical Stage Research Program (CLIN1) grant by the California Institute for Regenerative Medicine (CIRM) to advance its lead candidate RNDP-001 through IND submission in the next 12 months.
Lateral Pharma Pty. Ltd. has discovered peptides targeting LanC-like (LANCL) proteins reported to be useful for the treatment of diabetes, infections, inflammation, obesity, pain, metabolic, muscle and neurological disorders, among others.
Nurexone Biologic Inc. is developing Exopten as a minimally invasive Exotherapy for spinal cord injuries (SCI). The company's platform produces and loads exosomes with pharmaceutical cargo, targeting SCI intranasally in the case of lead product Exopten.
Cerevance Inc. has expanded its series B financing with an additional close of US$51 million, bringing the total series B financing to US$116 million. The proceeds will be used to advance Cerevance's therapeutics for central nervous system (CNS) diseases developed using its proprietary Nuclear Enriched Transcript Sort sequencing (Netsseq) platform.
RSS
